Luyckx A S, Gaspard U J, Romus M A, Grigorescu F, De Meyts P, Lefèbvre P J
Fertil Steril. 1986 May;45(5):635-42. doi: 10.1016/s0015-0282(16)49334-9.
Blood glucose and pyruvate, plasma insulin, and glucagon levels as well as erythrocyte insulin receptors were measured during an oral glucose tolerance test in 38 normal women before and after 6 months' use of one of three new oral contraceptives containing low doses of 19 nortestosterone-derived progestogens, levonorgestrel, and desogestrel. A slight deterioration of glucose tolerance was observed, with the area under the glucose curve increasing by only 7%, 9%, and 12% after Ovidol (Aaciphar SA, Brussels, Belgium), Marvelon (Organon, SA, Brussels, Belgium), and Trigynon (Schering SA, Brussels, Belgium) administration, respectively. We did not find any argument in favor of the development of a state of insulin resistance in women using these compounds, because erythrocyte receptor binding was not modified and plasma insulin responses to glucose were decreased. The glucose-induced suppression of plasma glucagon levels seemed less effective for treatment with the desogestrel-containing preparations than with the levonorgestrel-containing oral contraceptives.
在38名正常女性口服葡萄糖耐量试验期间,测量了她们在使用三种含低剂量19 - 去甲睾酮衍生孕激素(左炔诺孕酮和去氧孕烯)的新型口服避孕药之一6个月前后的血糖、丙酮酸、血浆胰岛素和胰高血糖素水平以及红细胞胰岛素受体。观察到葡萄糖耐量略有恶化,分别服用奥维朵(比利时布鲁塞尔Aaciphar SA公司)、妈富隆(比利时布鲁塞尔Organon SA公司)和特居乐(比利时布鲁塞尔先灵公司)后,葡萄糖曲线下面积仅分别增加了7%、9%和12%。我们没有发现任何证据支持使用这些化合物的女性会出现胰岛素抵抗状态,因为红细胞受体结合未改变,且血浆胰岛素对葡萄糖的反应降低。与含左炔诺孕酮的口服避孕药相比,含去氧孕烯制剂对葡萄糖诱导的血浆胰高血糖素水平的抑制作用似乎较弱。